|
STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - ViciniVax |
Research Funding - Aduro Biotech; Bionovion |
| |
|
Honoraria - AstraZeneca/MedImmune; Roche |
Consulting or Advisory Role - AstraZeneca/MedImmune; Clovis Oncology; Pfizer; Roche |
Speakers' Bureau - Clovis Oncology; Pfizer |
Research Funding - AstraZeneca |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |